Bio-Techne Corp. (TECH) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1151253,
    "name": "Bio-Techne Corp.",
    "stock_name": "Bio-Techne Corp.",
    "full_name": "Bio-Techne Corp.",
    "name_url": "stocks-analysis/bio-techne-corp",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "63.54",
    "chg": 0.59,
    "chgp": "0.94%",
    "dir": 1,
    "prev_price": "62.95",
    "mcapval": "8,416.79",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US09073M1045",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "923.63 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bio-techne-corp-1151253-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Bio-Techne Corp. Forms Golden Cross, Signaling Potential Bullish Breakout",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bio-techne-corp-forms-golden-cross-signaling-potential-bullish-breakout-3658970",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/BioTechneCorp_goldencross_3658970.png",
        "date": "2025-10-30 15:34:45",
        "description": "Bio-Techne Corp. has recently achieved a Golden Cross, indicating a potential shift in momentum within the Pharmaceuticals & Biotechnology sector. While the company has faced challenges over the past year, recent short-term performance shows resilience, suggesting increased investor interest and a possible favorable market position ahead."
      },
      {
        "title": "Is Bio-Techne Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bio-techne-corp-overvalued-or-undervalued-3637248",
        "imagepath": "",
        "date": "2025-10-21 11:58:31",
        "description": "As of 17 October 2025, the valuation grade for Bio-Techne Corp. has moved from expensive to very expensive, indicating a significant shift in its perceived value. The company appears to be overvalued based on its current metrics, including a P/E ratio of 37, a Price to Book Value of 3.78, and an EV to EBITDA of 20.54. In comparison, peers such as Illumina, Inc. and BioMarin Pharmaceutical, Inc. have P/E ratios of 19.09 and 15.17, respectively, highlighting Bio-Techne's premium valuation relative to its industry.\n\nThe company's recent stock performance has been underwhelming, with a year-to-date return of -14.12%, contrasting sharply with the S&P 500's gain of 13.30% over the same period. Additionally, over the past three years, Bio-Techne's stock has declined by 79.11%, while the S&P 500 has increased by 81.19%, further reinforcing the notion that the stock is overvalued in its current state...."
      },
      {
        "title": "Is Bio-Techne Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bio-techne-corp-overvalued-or-undervalued-3631657",
        "imagepath": "",
        "date": "2025-10-19 11:54:17",
        "description": "As of 17 October 2025, the valuation grade for Bio-Techne Corp. has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is considered overvalued based on its high P/E ratio of 37, a Price to Book Value of 3.78, and an EV to EBITDA of 20.54. In comparison, peers such as Illumina, Inc. and BioMarin Pharmaceutical, Inc. have P/E ratios of 19.09 and 15.17, respectively, highlighting the relative overvaluation of Bio-Techne.\n\nDespite a recent strong performance with a 1-week return of 5.46% compared to the S&P 500's 1.70%, the longer-term outlook remains concerning, with a YTD return of -14.12% versus the S&P 500's 13.30%. This suggests that while there may be short-term gains, the overall valuation metrics indicate that Bio-Techne Corp. is overvalued in the current market context...."
      },
      {
        "title": "Bio-Techne Corp. Experiences Revision in Stock Evaluation Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bio-techne-corps-technical-trend-shifts-from-bearish-to-sideways-amid-stock-price-decline-3600883",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/BioTechneCorp_technicaldot_3600883.png",
        "date": "2025-10-07 19:24:45",
        "description": "Bio-Techne Corp., a small-cap company in the Pharmaceuticals and Biotechnology sector, has recently adjusted its evaluation amid challenging market conditions. The stock has experienced a significant decline over the past year, contrasting with the S&P 500's performance, while technical indicators show mixed signals regarding its future trajectory."
      },
      {
        "title": "Is Bio-Techne Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bio-techne-corp-technically-bullish-or-bearish-3593439",
        "imagepath": "",
        "date": "2025-10-06 11:58:08",
        "description": "As of 3 October 2025, the technical trend for Bio-Techne Corp. has changed from bearish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The MACD is mildly bullish on both weekly and monthly time frames, while the Dow Theory also indicates a mildly bullish stance. However, the daily moving averages are mildly bearish, and the Bollinger Bands show a bullish weekly but mildly bearish monthly outlook. The KST is bullish weekly but bearish monthly, and the OBV reflects a mildly bullish weekly trend but mildly bearish monthly. \n\nIn terms of performance, Bio-Techne has significantly underperformed the S&P 500 over the longer term, with a year-to-date return of -12.61% compared to the S&P 500's 14.18%, and a three-year return of -78.52% versus the S&P 500's 82.57%...."
      },
      {
        "title": "Is Bio-Techne Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bio-techne-corp-technically-bullish-or-bearish-3591514",
        "imagepath": "",
        "date": "2025-10-05 11:43:06",
        "description": "As of 3 October 2025, the technical trend for Bio-Techne Corp. has changed from bearish to sideways. The current stance is neutral, with mixed signals across various indicators. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish. However, the daily moving averages indicate a mildly bearish trend. The Bollinger Bands show a bullish signal on the weekly timeframe but are mildly bearish on the monthly. The KST is bullish weekly but bearish monthly, and the OBV is mildly bullish weekly and mildly bearish monthly. \n\nIn terms of returns, the stock has outperformed the S&P 500 over the past week and month, with returns of 21.41% and 18.02% respectively, but it has significantly underperformed over longer periods, including year-to-date and one-year returns of -12.61% and -14.93% compared to the S&P 500's 14.18% and 17.82%...."
      },
      {
        "title": "Bio-Techne Corp. Hits Day High with 10.2% Surge in Strong Intraday Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bio-techne-corp-hits-day-high-with-102-surge-in-strong-intraday-performance-3585832",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/BioTechneCorp_priceRelatedfactors_3585832.png",
        "date": "2025-10-01 16:05:38",
        "description": "Bio-Techne Corp. has seen a significant increase in its stock price today, contrasting with the modest rise of the S&P 500. While the company has shown positive short-term trends, it faces longer-term challenges. Strong management efficiency and high institutional holdings highlight its potential in the biotechnology sector."
      },
      {
        "title": "Is Bio-Techne Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bio-techne-corp-technically-bullish-or-bearish-3544850",
        "imagepath": "",
        "date": "2025-09-20 18:57:36",
        "description": "As of 12 September 2025, the technical trend for Bio-Techne Corp. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the daily moving averages and monthly MACD being bearish. The weekly MACD and KST show mild bullishness, but this is overshadowed by the overall bearish signals from the monthly indicators. The stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -26.43% versus the S&P 500's 12.22%, and a one-year return of -30.74% compared to the S&P 500's 17.14%...."
      },
      {
        "title": "Is Bio-Techne Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bio-techne-corp-overvalued-or-undervalued-3541579",
        "imagepath": "",
        "date": "2025-09-20 17:29:38",
        "description": "As of 7 July 2025, the valuation grade for Bio-Techne Corp. has moved from expensive to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, as evidenced by its P/E ratio of 37, which is higher than the peer average of 19.09 for Illumina, Inc. and 15.17 for BioMarin Pharmaceutical, Inc. Additionally, Bio-Techne's EV to EBITDA stands at 20.54, compared to Illumina's 13.83, further highlighting its premium valuation. The PEG ratio of 12.84 also suggests that the stock is priced excessively relative to its growth prospects.\n\nIn comparison to its peers, Bio-Techne Corp. is positioned unfavorably, with a higher P/E and EV to EBITDA ratios than its competitors, indicating that investors are paying a premium for its earnings and cash flows. The company's recent performance has been disappointing, with a year-to-date return of -26.43%, significantly underperfor..."
      }
    ],
    "total": 15,
    "sid": "1151253",
    "stock_news_url": "https://www.marketsmojo.com/news/bio-techne-corp-1151253"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Bio-Techne Corp. Forms Golden Cross, Signaling Potential Bullish Breakout

2025-10-30 15:34:45

Bio-Techne Corp. has recently achieved a Golden Cross, indicating a potential shift in momentum within the Pharmaceuticals & Biotechnology sector. While the company has faced challenges over the past year, recent short-term performance shows resilience, suggesting increased investor interest and a possible favorable market position ahead.

Is Bio-Techne Corp. overvalued or undervalued?

2025-10-21 11:58:31

As of 17 October 2025, the valuation grade for Bio-Techne Corp. has moved from expensive to very expensive, indicating a significant shift in its perceived value. The company appears to be overvalued based on its current metrics, including a P/E ratio of 37, a Price to Book Value of 3.78, and an EV to EBITDA of 20.54. In comparison, peers such as Illumina, Inc. and BioMarin Pharmaceutical, Inc. have P/E ratios of 19.09 and 15.17, respectively, highlighting Bio-Techne's premium valuation relative to its industry. The company's recent stock performance has been underwhelming, with a year-to-date return of -14.12%, contrasting sharply with the S&P 500's gain of 13.30% over the same period. Additionally, over the past three years, Bio-Techne's stock has declined by 79.11%, while the S&P 500 has increased by 81.19%, further reinforcing the notion that the stock is overvalued in its current state....

Is Bio-Techne Corp. overvalued or undervalued?

2025-10-19 11:54:17

As of 17 October 2025, the valuation grade for Bio-Techne Corp. has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is considered overvalued based on its high P/E ratio of 37, a Price to Book Value of 3.78, and an EV to EBITDA of 20.54. In comparison, peers such as Illumina, Inc. and BioMarin Pharmaceutical, Inc. have P/E ratios of 19.09 and 15.17, respectively, highlighting the relative overvaluation of Bio-Techne. Despite a recent strong performance with a 1-week return of 5.46% compared to the S&P 500's 1.70%, the longer-term outlook remains concerning, with a YTD return of -14.12% versus the S&P 500's 13.30%. This suggests that while there may be short-term gains, the overall valuation metrics indicate that Bio-Techne Corp. is overvalued in the current market context....

Bio-Techne Corp. Experiences Revision in Stock Evaluation Amid Market Challenges

2025-10-07 19:24:45

Bio-Techne Corp., a small-cap company in the Pharmaceuticals and Biotechnology sector, has recently adjusted its evaluation amid challenging market conditions. The stock has experienced a significant decline over the past year, contrasting with the S&P 500's performance, while technical indicators show mixed signals regarding its future trajectory.

Is Bio-Techne Corp. technically bullish or bearish?

2025-10-06 11:58:08

As of 3 October 2025, the technical trend for Bio-Techne Corp. has changed from bearish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The MACD is mildly bullish on both weekly and monthly time frames, while the Dow Theory also indicates a mildly bullish stance. However, the daily moving averages are mildly bearish, and the Bollinger Bands show a bullish weekly but mildly bearish monthly outlook. The KST is bullish weekly but bearish monthly, and the OBV reflects a mildly bullish weekly trend but mildly bearish monthly. In terms of performance, Bio-Techne has significantly underperformed the S&P 500 over the longer term, with a year-to-date return of -12.61% compared to the S&P 500's 14.18%, and a three-year return of -78.52% versus the S&P 500's 82.57%....

Is Bio-Techne Corp. technically bullish or bearish?

2025-10-05 11:43:06

As of 3 October 2025, the technical trend for Bio-Techne Corp. has changed from bearish to sideways. The current stance is neutral, with mixed signals across various indicators. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish. However, the daily moving averages indicate a mildly bearish trend. The Bollinger Bands show a bullish signal on the weekly timeframe but are mildly bearish on the monthly. The KST is bullish weekly but bearish monthly, and the OBV is mildly bullish weekly and mildly bearish monthly. In terms of returns, the stock has outperformed the S&P 500 over the past week and month, with returns of 21.41% and 18.02% respectively, but it has significantly underperformed over longer periods, including year-to-date and one-year returns of -12.61% and -14.93% compared to the S&P 500's 14.18% and 17.82%....

Bio-Techne Corp. Hits Day High with 10.2% Surge in Strong Intraday Performance

2025-10-01 16:05:38

Bio-Techne Corp. has seen a significant increase in its stock price today, contrasting with the modest rise of the S&P 500. While the company has shown positive short-term trends, it faces longer-term challenges. Strong management efficiency and high institutional holdings highlight its potential in the biotechnology sector.

Is Bio-Techne Corp. technically bullish or bearish?

2025-09-20 18:57:36

As of 12 September 2025, the technical trend for Bio-Techne Corp. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the daily moving averages and monthly MACD being bearish. The weekly MACD and KST show mild bullishness, but this is overshadowed by the overall bearish signals from the monthly indicators. The stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -26.43% versus the S&P 500's 12.22%, and a one-year return of -30.74% compared to the S&P 500's 17.14%....

Is Bio-Techne Corp. overvalued or undervalued?

2025-09-20 17:29:38

As of 7 July 2025, the valuation grade for Bio-Techne Corp. has moved from expensive to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, as evidenced by its P/E ratio of 37, which is higher than the peer average of 19.09 for Illumina, Inc. and 15.17 for BioMarin Pharmaceutical, Inc. Additionally, Bio-Techne's EV to EBITDA stands at 20.54, compared to Illumina's 13.83, further highlighting its premium valuation. The PEG ratio of 12.84 also suggests that the stock is priced excessively relative to its growth prospects. In comparison to its peers, Bio-Techne Corp. is positioned unfavorably, with a higher P/E and EV to EBITDA ratios than its competitors, indicating that investors are paying a premium for its earnings and cash flows. The company's recent performance has been disappointing, with a year-to-date return of -26.43%, significantly underperfor...

View All News